$heff's $tation of $tocks & $olid DD

[Stock H.O.G.]

PLX - $heff, Dr. Frost is indeed diverting his investment and here is proof of that....

http://www.www.istockanalyst.com/article/viewarticle/articleid/4846485

2. Opko Health, Inc. (OPK: 3.86, -0.05): $3.85

Shares of this medical appliances & equipment company were acquired by 2 insiders:

CEO & Chairman Phillip Frost M.D. acquired 1,158,000 shares, paying $3.55 per share for a total amount of $4.11 million.
Vice Chairman & CTO Jane Hsiao, Ph.D acquired 200,000 shares, paying $3.55 per share for a total amount of $710,000.
This is the second week in a row that Opko Health has made our list. In a note I sent out to subscribers in October I mentioned,

"Dr. Frost has been nibbling on small quantities of Opko stock every few days since the start of this year. These purchases were done indirectly through Frost Gamma Investments Trust. This relatively young Miami based company that was founded in 2006 has several potential drugs in Phase II and Phase III trials. The company also develops medical devices, vaccines and ophthalmic imaging systems. Revenue at Opko has been rising over the last several quarters but the company is still unprofitable and at its current run rate could run out of cash in less than a year unless revenue ramps up significantly. The stock has been rising steadily throughout this year in lockstep with Dr. Frost's purchases.

The 73 year old Dr. Frost has had a distinguished career, serving as the CEO of IVAX Corporation from 1987 to 2006 before it was acquired by SINLetter portfolio holding Teva Pharmaceuticals (TEVA: 55.38, -0.32). He is currently the Vice-Chairman of Teva Pharmaceuticals (TEVA). He also serves on the boards of Northrop Grumman (NOC), Ladenburg Thalmann Financial Services (LTS) and Castle Brands amongst many others. I will definitely add OPK to my watch list for further research."

Mr. Frost's shares were acquired indirectly through Frost Gamma Investments Trust, of which Phillip Frost is the trustee. Ms. Jane's shares were acquired indirectly through Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment.

P/E: N/A Forward P/E: N/A Industry P/E: 26.98
P/S: 34.25 Price/Book: 50.89 EV/EBITDA: -55.26
Market Cap: $983.12M Avg. Daily Volume: 492,369 52 Week Range: $